GLW plunged -15.08% during Tuesday's regular session after reporting Q2 results that beat estimates but issuing Q3 revenue guidance that fell slightly short of elevated Street expectations. Q2 core EPS of $0.78 on $4.74B in core sales topped consensus, yet Q3 revenue guidance of $4.9B–$5.0B (midpoint $4.95B) came in just below the ~$5B analysts had penciled in.

SHAZ plunged -18.47% during regular trading hours on Tuesday, dropping from a prior close of $58.79 to $47.93, extending a multi-week rout that has erased more than half its value since early July peaks near $97. The selloff follows yesterday's -9.40% decline and reflects mounting investor anxiety ahead of the company's Q2 2026 earnings announcement, after Q1 results missed estimates with an EPS of -$1.43 versus -$0.89 expected and negligible revenue of just $1.54 million TTM.

CVLT shares plunged -15.94% during Tuesday's regular session, despite reporting fiscal Q1 (June quarter) results that beat on both adjusted EPS ($1.42 vs. $1.16 consensus) and revenue ($314.1M vs. $310.5M consensus). The sell-off was triggered by a significant miss on annual recurring revenue (ARR), which came in at $1.05 billion versus the $1.15 billion analysts had projected, while billings declined -5.9% year-over-year.

SANM plunged -19.52% during regular trading on Tuesday after reporting Q3 FY2026 results that beat on both EPS ($3.31 vs. $2.79 consensus) and revenue ($3.46B vs. $3.40B), yet disappointed with forward guidance. The selloff was driven by Q4 revenue guidance of $3.3B–$3.6B (midpoint $3.45B), which came in below the $3.52B analyst consensus, alongside a lower ZT Systems Q4 revenue outlook of $0.8B–$1.0B due to legacy program timing shifts.

REPL crashed -32.1% during regular trading on Tuesday after FDA briefing documents cast serious doubt on the efficacy of its lead skin cancer drug candidate RP1 (vusolimogene oderparepvec). The FDA reviewers stated the single-arm IGNYTE trial design makes it impossible to determine whether RP1 contributed any meaningful benefit beyond Bristol Myers Squibb's Opdivo alone, calling the overall survival data "not interpretable."

AMKR plunged -24.08% during Tuesday's regular session, falling from a $60.71 prior close to $46.09, as a post-earnings sell-off accelerated throughout the trading day. The primary catalyst was disappointing Q3 revenue guidance of $1.95B–$2.05B (midpoint $2.0B), which fell well short of the $2.1B consensus, overshadowing a strong Q2 beat of $0.70 EPS on record $1.9B revenue.

Oracle Corporation (ORCL) closed at approximately $120 on July 27, 2026, down roughly 63% from its September 2025 all-time high of $345.72. The $250 price target aligns with the consensus analyst 12-month forecast of approximately $248, implying potential upside exceeding 100% from current levels.

Both BBUS and VOO are low-cost, passively managed exchange-traded funds (ETFs) providing broad exposure to U.S. equities, making them suitable for core portfolio allocations. BBUS tracks the Morningstar U.S. Target Market Exposure Index, targeting approximately 85% of the U.S. equity market by capitalization with around 546 holdings that include large- and mid-cap stocks.

Both SPY and VOO track the S&P 500 Index, providing nearly identical exposure to large-cap U.S. equities across all sectors. VOO offers a significantly lower expense ratio of 0.03% compared to SPY at 0.0945%, resulting in lower ongoing costs for long-term investors.

Both QQQ and QQQM track the Nasdaq-100 Index, delivering identical underlying exposure to large-cap growth companies with a heavy emphasis on technology and innovation. QQQM offers a lower expense ratio of 0.15% compared to 0.18% for QQQ , providing a modest but compounding cost advantage for long-term holders.

Both ETFs provide concentrated exposure to the semiconductor sector through passive index strategies, but differ in index construction, with SHOC tracking approximately 30 holdings and SMH tracking 25 holdings. SHOC maintains a stricter focus on U.S.-listed semiconductor companies, while SMH includes select U.S.-listed foreign issuers such as Taiwan Semiconductor Manufacturing Company (TSMC), offering marginally broader geographic representation within the same industry.

NVTS shares plunged -10.96% to $10.16 during Tuesday's regular session, following a -2% to -3% after-hours decline Monday after the company reported Q2 2026 earnings. The primary catalyst was a Q2 GAAP net loss of $228.2 million ($0.95/share), which included a $203.1 million non-cash earnout liability charge that dramatically overshadowed a revenue beat of $10.53M vs. $9.84M expected.

Navitas Semiconductor (NVTS) shares fell approximately 34% over the last 30 days, driven primarily by a patent infringement lawsuit filed by competitor Wolfspeed on July 7, 2026. The lawsuit targets five core Navitas product lines — including GaNFast, GaNSlim, GaNSafe, GeneSiC MOSFETs, and SiCPAK modules — and seeks a permanent U.S. sales and import ban.

DELL tumbled -14.55% during Tuesday's regular session, plunging from Monday's close of $426.91 to $364.79 as a global memory-chip rout spilled into AI infrastructure names. The selloff was triggered by Chinese DRAM maker ChangXin Memory Technologies' (CXMT) blockbuster Shanghai IPO, which surged +466% on debut and raised fears of aggressive Chinese capacity expansion disrupting global memory pricing.

ARM shares plunged approximately -8.4% during regular trading Tuesday, extending premarket weakness after a global semiconductor sell-off swept through Asian and European markets overnight. The rout was sparked by a report that a Chinese firm achieved mass production of DUV lithography technology, threatening ASML's dominance and intensifying fears of overstretched AI-sector valuations.

LRCX fell -8.22% to $267.64 during regular trading on July 28, extending Monday's -4.46% decline and marking a brutal two-day semiconductor equipment rout. The primary catalyst was a global chip-sector selloff sparked by reports that a Chinese state-backed firm has begun mass-producing immersion DUV lithography machines, directly threatening ASML's near-monopoly and by extension the entire Western equipment ecosystem.

PLTR dropped -9.77% during regular trading Tuesday, falling to $118.68 from Monday's close of $131.53, nearly erasing the prior session's +7.00% rally. The primary catalyst was a Financial Times report citing a Health Foundation analysis that found Palantir's NHS patient discharge tracking software showed no measurable impact, contradicting earlier claims of a 15% improvement and intensifying scrutiny of the £330M UK contract.

AMAT dropped -6.82% during Tuesday's regular session, extending Monday's -3.61% decline, with the stock sliding from a prior close of $516.89 to roughly $481.63 by mid-morning. The primary catalyst is a report that a Chinese state-backed manufacturer has begun producing domestic immersion DUV lithography machines, threatening the China revenue base of Western chip equipment suppliers including Applied Materials.

INTC fell -5.79% to $86.36 during Tuesday's regular session, extending a multi-session slide that has erased over 38% from its June 22 peak near $141. The sell-off was triggered by a rout in Asian semiconductor stocks, where South Korea's Kospi plunged 10.8% and trading was halted after Samsung and SK Hynix each dropped over 13%.

AMD fell -7.85% during Tuesday's regular session, deepening Monday's -5.17% loss as a sector-wide semiconductor rout accelerated at the open. The primary catalyst was Chinese memory chipmaker CXMT's explosive Shanghai IPO, surging +466% to a ~$487 billion valuation and stoking fears of intensified competition for U.S. chipmakers.